Trials / Completed
CompletedNCT02038933
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCT
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab |
Timeline
- Start date
- 2014-03-05
- Primary completion
- 2016-04-08
- Completion
- 2020-10-08
- First posted
- 2014-01-17
- Last updated
- 2021-10-14
- Results posted
- 2017-05-30
Locations
46 sites across 12 countries: United States, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Singapore, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02038933. Inclusion in this directory is not an endorsement.